Business

AstraZeneca eyes Bristol Myers merger for $400B U.S. scale

1 min read

AstraZeneca eyes Bristol Myers merger for $400B U.S. scale
Photo: Parrish Freeman · Unsplash
0 0
XWhatsAppTelegramLinkedIn

AstraZeneca reportedly held preliminary merger talks with U.S. rival Bristol Myers Squibb, according to reports from the Financial Times and Reuters on August 6, 2026. CNBC has not independently confirmed the discussions, and a senior source later denied the talks to Reuters.

Sources

Report / request removal

Related

Comments

No comments yet. Be the first.